Recursion Pharma says its AI-discovered oral candidate REC-4881 produced sustained reductions in colon polyp burden for patients with familial adenomatous polyposis. Nine of 11 trial participants experienced a median 53% drop in total polyp burden measured 12 weeks after stopping treatment, following earlier data showing a 43% decline during therapy. The Nvidia-backed company will expand adult enrollment and plans to consult the U.S. regulator in H1 2026 about a potential pivotal study. These are encouraging early results that need confirmation in larger trials.
Recursion's AI-Discovered Drug REC-4881 Shrinks Colon Polyps 53% in Early Trial
07:27 PM, 12/08/2025
Similar Articles
Two FDA-Approved Cancer Drugs, Combined, Reduce a Key Alzheimer’s Protein in Mice — 1.4M Health Records Helped Point the Way
UCSF researchers used gene-expression screening and 1.4 million anonymized health records to repurpose existing drugs for Alz...
Biotechs in Próspera Pursue Combination Gene‑Therapies to Tackle Ageing
Próspera, a Honduran charter city on Roatán island, has drawn longevity startups by offering a permissive regulatory environm...
Respiratory Cell & Gene Therapy: Why Progress Lags — and What Could Change Next
Key points: Venture funding for CGTs dropped from $35.9bn in 2021 to $23.3bn in 2024, driven by trial failures and manufactur...
Daily Oral GLP‑1 Pill Cuts About 10% of Body Weight in 18 Months, Study Finds
Trial results: Orforglipron, an investigational oral GLP‑1, produced about 10% average body‑weight loss after 72 weeks in adu...
Tirzepatide Quieted 'Food Noise' in a Brain-Recorded Case — Effect Wore Off After Several Months
This small brain-recording case followed a 60-year-old woman with obesity and loss-of-control eating who was taking tirzepati...
FDA’s Proposed Gene‑Therapy Pathway Could Accelerate Bespoke Treatments — Key Questions Remain
Summary: The FDA has proposed a pathway that could speed personalised gene therapies when a clear molecular defect is targete...
Experimental Compound Blocks RAGE–DIAPH1 Pathway, Reduces Inflammation and Speeds Wound Healing in Diabetic Models
Study: An experimental compound blocks the RAGE–DIAPH1 interaction, lowering inflammation and improving wound healing in diab...
Kentucky Researchers Convert Alzheimer’s Risk Gene to Protective Form in Mice — A Promising Proof of Concept
The University of Kentucky led a 22-person team that used gene editing to convert an Alzheimer’s risk form of the APOE gene t...
Linker Breakthroughs at CPHI 2025 Unlock Greater Stability and New Payloads for ADCs
At CPHI 2025, experts reported that innovations in linker chemistry are enabling more stable and selective ADCs and expanding...
MEOW-1 Trial Tests Microchip-Sized GLP-1 Implant to Reduce Obesity in Cats
Okava Pharmaceuticals has launched MEOW-1, a trial of a microchip-sized implant that releases a GLP-1 drug over three months ...
Orléans Lab Pioneers mRNA + Ultrasound 'Bunker-Buster' Strategy Against Pancreatic Cancer
Researchers at INSERM's ART laboratory in Orléans are developing mRNA-based approaches to treat aggressive cancers, especiall...
University of Illinois Develops Imaging Tool to Reduce Cancer Re-Operations
University of Illinois engineers built a prototype imaging system that helps surgeons detect residual cancer cells during ope...
After 12 Surgeries, Teen's Recurring Vocal Cord Tumors Stop After Immunotherapy — Papzimeos Later FDA-Approved
Savanna Branham developed persistent hoarseness at 13 and was diagnosed with recurrent respiratory papillomatosis (RRP), a ra...
Old Drug, New Hope: Arginine Reduces Alzheimer’s Plaques and Restores Cognition in Mice
This Japanese study found that orally administered arginine—an amino acid already used in some treatments—reduced amyloid‑bet...
Eli Lilly Secures Global Rights to MeiraGTx’s AAV‑AIPL1 Gene Therapy in Deal Worth Up to $475M
MeiraGTx has granted Eli Lilly worldwide rights to its experimental AAV-AIPL1 gene therapy in a deal that could exceed $475 m...